Clinical Trials
22 trialsNCT07209189 2026-04-23
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT01898494 2026-04-01
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT07418034 2026-02-18
SAVED
University of Maryland, Baltimore
Phase 2 Not yet recruiting
NCT07033091 2026-02-13
Prevalence of Human Papillomavirus (HPV) in a Healthy Population: A Feasibility Study of Oropharyngeal Cancer Screening
The Institute of Molecular and Translational Medicine, Czech Republic
Phase NA Recruiting
NCT01932697 2026-02-10
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Mayo Clinic
Phase 2 Completed
NCT01302834 2026-01-12
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04124198 2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA Active not recruiting
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05388773 2025-06-19
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT02827838 2025-03-17
Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
Wake Forest University Health Sciences
Phase EARLY_PHASE1 Terminated
NCT06797986 2025-01-29
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC.
Cellid Co., Ltd.
Phase 1/2 Not yet recruiting
NCT02258659 2024-09-24
OPTIMA
University of Chicago
Phase 2 Completed
NCT01084083 2023-06-28
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03258008 2022-12-16
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01891695 2022-10-12
OPSCC N0 Nodal Control With Reduced IMRT
University of Virginia
Phase NA Terminated
NCT04015336 2022-02-24
E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02981862 2021-08-31
CaptHPV
Institut de Cancérologie de Lorraine
Phase NA Completed
NCT04044950 2020-09-22
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03346915 2019-10-09
Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention
Boston Medical Center
Phase NA Completed
NCT02706691 2019-04-16
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
University of Chicago
Phase 2 Terminated
NCT02048020 2018-08-14
Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01585428 2018-03-07
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed